Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic

Fig. 3

Cumulative incidence of first-time AEs ≥ Grade 3 after January 2020. a All AEs ≥ Grade 3, b Category of AEs ≥ Grade 3. The figure shows the cumulative incidence of the first-time AEs ≥ Grade 3 occurring after ICI administration during a 3-year period from January 1, 2020 to December 31, 2022. Overall, first-time AEs ≥ Grade 3 occurred in 265 patients from a population of 472 (excluding 55 patients who received an ICI prior to January 1, 2020, and for whom the onset date of their first AE was unknown [527–55 = 472). The vertical line at 456 days corresponds to April 1, 2021. The shaded area shows the 95% confidence interval

Back to article page